article thumbnail

Sophia Genetics launches AI tool to find COVID-19 ‘unknowns’

pharmaphorum

Swiss medical data specialist Sophia Genetics has launched a platform that will sift through data generated at more than 1,000 hospitals around the world to try to work out how the COVID-19 pandemic will evolve in the coming months and years. The post Sophia Genetics launches AI tool to find COVID-19 ‘unknowns’ appeared first on.

Genetics 136
article thumbnail

Can genetic data be a magic bullet for drug R&D?

pharmaphorum

Drug development has long been an issue for the pharma industry, due to the expense and the high failure rate of potential treatments. Ben Hargreaves finds that the vast amount of genetic data that exists today could help provide a faster, more targeted way of developing new drug candidates.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

New podcast on the future for genomics and big data

Drug Discovery World

This is the latest episode of the free DDW narrated podcast, “What lies in the future for genomics and big data?”, and “ Why a recent advancement is a giant leap for human genomics ”. Listen here: The post New podcast on the future for genomics and big data appeared first on Drug Discovery World (DDW).

article thumbnail

Gene editing: beyond the hype

pharmaphorum

Genome editing is an exciting but still nascent field, and companies in the area face as many obstacles as they do opportunities. Sangamo CEO Sandy Macrae told us how his company is being cautious about the hype and finding ways to be financially viable in an emerging space. The genomic medicine journey.

article thumbnail

GSK turns to AI specialist Tempus for R&D productivity boost

pharmaphorum

US-based Tempus has built a precision medicine platform – powered by artificial intelligence and machine learning – that sifts through a large library of anonymised patient data, including results of clinical, molecular, and genomic testing.

article thumbnail

AstraZeneca builds its AI capabilities again with Illumina tie-up

pharmaphorum

Overall, the aim is to improve the efficiency of drug discovery by identifying genetic variants that contribute to human disease in omics data – a broad category that includes DNA profiles, gene transcripts, and protein expression.

Genome 64
article thumbnail

Drug development and working with specialised Rare Disease networks

pharmaphorum

In a recent webinar held by pharmaphorum, in partnership with IQVIA, a discussion was held looking at how to make academic and commercial medical research more efficient, while also looking at the opportunity of genomic data to bring benefits to patients and healthcare systems. The potential to leverage genomic data.